News Releases

Mar 02, 2017
OncoMed Announces Multiple Abstracts Related to Anti-TIGIT Program Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2017

REDWOOD CITY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical immuno-oncology and anti-cancer stem cell therapeutic candidates in a total of six presentations at the upcoming American Association for Cancer Research (AACR) Meeting to be held April 1-5, 2017 in Washington, DC.

Among the presentations will be three posters detailing preclinical data for OncoMed's novel anti-TIGIT (OMP-313M32) immuno-oncology therapeutic candidate.  These will be the first data that the company has shared publicly for its anti-TIGIT antibody program.  New data will also be presented on biomarker research associated with the Phase 1b portion of OncoMed's tarextumab (anti-Notch2/3, OMP-59R5) clinical trial in small cell lung cancer and OncoMed's preclinical GITRL-Fc trimer (OMP-336B11) program.  In addition, xenograft data will be presented for anti-RSPO3 (OMP-131R10) in combination with taxane chemotherapy in colorectal cancer.

The following abstracts have been selected for presentation by OncoMed scientists:

Sunday, April 2, 2017               1:00 PM — 5:00 PM
Title: Pharmacodynamic biomarkers for anti-TIGIT treatment and prevalence of TIGIT expression in multiple solid tumor types
Presenting author: Fiore Cattaruzza, Pharm. D., Ph.D., Senior Scientist II, Translational Medicine
Abstract Number: 599
Session: T-cell Immunity to Cancer: New Progress
Location: Poster section 26; Poster board 3

Monday, April 3, 2017               8:00 AM - Noon
Title: Antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains) induces anti-tumor immune response and generates long-term immune memory
Presenting author: Angie Inkyung Park, Ph.D., Senior Director Immunotherapy
Abstract Number: 2003
Session: Tumor Microenvironment
Location: Poster section 44; Poster board 18

Title: Circulating Tumor Cells (CTCs) in patients with extensive-stage small cell lung cancer and their association with clinical outcome  
Abstract number: 1727
Presenting author: Chun Zhang, Ph.D., Director, Translational Medicine
Session: Liquid Biopsies 1: Circulating Tumor Cells
Location: Poster section 30; Poster board 17

Title: R-SPONDIN3 antagonism sensitizes colorectal cancer to taxane treatment
Abstract Number: 1911
Presenting author: Marcus Fischer, Scientist
Session: Normal and Neoplastic Stem Cells
Location: Poster section 41; Poster board 12

Monday, April 3, 2017               1:00 PM — 5:00 PM
Title: Anti-TIGIT induces T cell mediated anti-tumor immune response and combines with immune checkpoint inhibitors to enhance strong and long term anti-tumor immunity
Abstract number: 2612
Presenting author: Minu Srivastava, Ph.D., Senior Scientist II
Session: Checkpoints 2: Small Molecule Inhibitors (Note: anti-TIGIT is a monoclonal antibody)
Location: Poster section 25; Poster board 1

Wednesday, April 5, 2017         8:00 AM - Noon
Title: Prevalence of GITR expression and pharmacodynamic (PD) biomarkers in syngeneic tumor models treated by a GITR agonist (GITRL-Fc)
Abstract number: 5621
Presenting author: Min Wang, Ph.D., Director, Translational Medicine
Session: Immune Checkpoints and Immunosurveillance
Location: Poster section 25; Poster board 23

About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics.  OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis.  Demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), anti-DLL4/VEGF bispecific (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), anti-RSPO3 (OMP-131R10) and anti-TIGIT (OMP-313M32) are part of the company's strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK).  OncoMed is independently developing brontictuzumab (anti-Notch1, OMP-52M51) and GITRL-Fc (OMP-336B11), as well as continuing to pursue new drug discovery research efforts.  For further information about OncoMed Pharmaceuticals, please see www.oncomed.com.

Contact:
Michelle Corral
Senior Director, Investor Relations and Corporate Communications
OncoMed Pharmaceuticals 
michelle.corral@oncomed.com
(650) 995-8373

OncoMed Pharmaceuticals, Inc. is a wholly-owned subsidiary of Mereo BioPharma Group plc.
Please visit our parent site www.mereobiopharma.com for our Pipeline, Partnering Opportunities and Investors information.